MeCP2 Is an Epigenetic Factor That Links DNA Methylation with Brain Metabolism
International Journal of Molecular Sciences · 20.02.2023 · 24 (4) · 4218
DOI: 10.3390/ijms24044218 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.02.2023. Verfasst von Yen My Vuu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB …. Hauptthemen laut MEDLINE: Brain, DNA Methylation, Epigenesis, Genetic, Methyl-CpG-Binding Protein 2. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Ontario Rett Syndrome Association, Children Hospital Research Institute of Manitoba.
Abstract (Originalsprache)
DNA methylation, one of the most well-studied epigenetic modifications, is involved in a wide spectrum of biological processes. Epigenetic mechanisms control cellular morphology and function. Such regulatory mechanisms involve histone modifications, chromatin remodeling, DNA methylation, non-coding regulatory RNA molecules, and RNA modifications. One of the most well-studied epigenetic modifications is DNA methylation that plays key roles in development, health, and disease. Our brain is probably the most complex part of our body, with a high level of DNA methylation. A key protein that binds to different types of methylated DNA in the brain is the methyl-CpG binding protein 2 (MeCP2). MeCP2 acts in a dose-dependent manner and its abnormally high or low expression level, deregulation, and/or genetic mutations lead to neurodevelopmental disorders and aberrant brain function. Recently, some of MeCP2-associated neurodevelopmental disorders have emerged as neurometabolic disorders, suggesting a role for MeCP2 in brain metabolism. Of note, MECP2 loss-of-function mutation in Rett Syndrome is reported to cause impairment of glucose and cholesterol metabolism in human patients and/or mouse models of disease. The purpose of this review is to outline the metabolic abnormalities in MeCP2-associated neurodevelopmental disorders that currently have no available cure. We aim to provide an updated overview into the role of metabolic defects associated with MeCP2-mediated cellular function for consideration of future therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
ORCID-Profile: Mojgan Rastegar
Förderung
- CIHR
- Ontario Rett Syndrome Association
- Children Hospital Research Institute of Manitoba
- ENRRICH
- University of Manitoba Research Grant Program
- University of Manitoba Collaborative Research Program
- Natural Sciences and Engineering Research Council
- Canadian Institutes of Health Research (CIHR)
Zitieren
APA
Vuu, Y. M., Roberts, C. T., & Rastegar, M. (2023). MeCP2 Is an Epigenetic Factor That Links DNA Methylation with Brain Metabolism. International Journal of Molecular Sciences, 24(4), 4218. https://doi.org/10.3390/ijms24044218
Vancouver
Vuu YM, Roberts CT, Rastegar M. MeCP2 Is an Epigenetic Factor That Links DNA Methylation with Brain Metabolism. International Journal of Molecular Sciences. 2023;24(4):4218. doi:10.3390/ijms24044218
BibTeX
@article{Vuu2023,
author = {Vuu, Yen My and Roberts, Chris-Tiann and Rastegar, Mojgan},
title = {MeCP2 Is an Epigenetic Factor That Links DNA Methylation with Brain Metabolism},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {4},
pages = {4218},
doi = {10.3390/ijms24044218}
}
EUVIMED